Last reviewed · How we verify
NCT05976945
Imagery Rescripting as Treatment for Depression
NA trial testing Imagery Rescripting in Major Depressive Disorder in 10 participants. Currently enrolling.
1 August 2026
Quick facts
| Lead sponsor | University of Amsterdam |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 10 |
| Start date | 10 August 2023 |
| Primary completion | 1 August 2026 |
| Estimated completion | 1 August 2027 |
| Sites | 1 location across Netherlands |
Drugs / interventions tested
- Imagery Rescripting
Conditions studied
- Major Depressive Disorder — all drugs for Major Depressive Disorder →
- Persistent Depressive Disorder — all drugs for Persistent Depressive Disorder →
Sponsor
University of Amsterdam
Who can join
Adults 18 to 65, any sex, with Major Depressive Disorder or Persistent Depressive Disorder. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this multiple baseline case series study is to test Imagery Rescripting in depression. The main question\[s\] it aims to answer are: * does Imagery Rescripting lead to a reduction of depression and of believability of negative beliefs held by the participants? * does Imagery Rescripting also leads to reductions in worrying and brooding? * Participants will wait for 6-10 weeks (to assess time effects without treatment), followed by 5 weekly preparation sessions, 8-12 weekly Imagery Rescripting sessions, and 5 weeks post-treatment. * Participants will rate the believability of 3-5 core dysfunctional beliefs related to their depression as well as 2 items assessing depression severity on a weekly basis. In addition, they will fill out more extensive questionnaires on depression, worry and brooding before each phase, as well as at 5 weeks post-treatment, and 6 and 12 months follow-up.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05976945
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Imagery Rescripting
Trials testing the same drug.
- NCT07362511 — Imagery Rescripting in Primary Care · NA · recruiting
- NCT07196085 — Neural Mechanisms and Efficacy of Imagery Rescripting for Fear of Failure · NA · completed
- NCT07048756 — Psychotherapeutic Imagery Techniques · NA · completed
- NCT03607630 — Can Imagination Change Upsetting Memories of Trauma? · Phase 1, PHASE2 · unknown
Other recruiting trials for Major Depressive Disorder
Currently open trials in the same condition.
- NCT07219394 — Peer-Delivered Behavioral Activation in a CCBHC · NA · recruiting
- NCT06705478 — Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disor · Phase 2 · recruiting
- NCT06749392 — An Individual-specific Synchrony Signature · NA · recruiting
- NCT07316803 — Group Intervention for Romantic Relationships in Young Adults With Severe Mental Illness · NA · recruiting
- NCT07242105 — Optimizing Brain Excitability in Depression · NA · recruiting
Other University of Amsterdam trials
Trials by the same sponsor.
- NCT07505238 — Informing Patients About Their Surgery's Environmental Impact: an Effective Pathway to Sustainable Healthcare? · NA · not yet recruiting
- NCT07362511 — Imagery Rescripting in Primary Care · NA · recruiting
- NCT06966323 — Hold me Tight/Let me Go: Effectiveness of a Course to Enhance Parent-adolescent Relationship · recruiting
- NCT06336551 — Acceptance and Commitment Therapy for Insomnia · NA · completed
- NCT05986552 — The Influence of Treatment Format on Schema Therapy for Borderline Personality Disorder · NA · enrolling by invitation
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05976945 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Amsterdam
- Last refreshed: 20 January 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05976945.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing